Department of Public Health and Primary Care, Academic Center for General Practice, KU Leuven, Leuven, Belgium.
Front Public Health. 2022 Sep 23;10:1014734. doi: 10.3389/fpubh.2022.1014734. eCollection 2022.
Contrary to most European guidelines, benzodiazepine receptor agonists (BZRA) are often used continuously at a low dosage, being the most common form of long-term use. In Belgium, BZRA use is monitored by analyzing self-report data about medication use in the last 24 h. This method provides insufficient insight into the terms of use of these psychoactive drugs.
To describe trends in BZRA prescribing in Flanders, Belgium, between 2000 and 2019.
Population-based trend analysis and a case-control study for the year 2019 were done with data from a morbidity registry in general practice.
Repeated cross-sectional and joinpoint regression analyses revealed trends in sex- and age-standardized prescription rates among adult patients (18+).
Overall, BZRA prescriptions increased. The highest overall increase was found among male patients 18-44 years old, with an average annual percentage change of 2.5 (95% CI: 0.9, 4.3). Among 65+ female patients, a decrease was found since 2006, with an annual percentage change of -0.7 (95% CI: -1.3, -0.1). In 2019, 12% of registered patients received minimally one prescription, long-term use was observed in 5%, back pain was the most common morbidity significantly associated with a rise in BZRA prescriptions, and zolpidem was the most prescribed BZRA (22%).
Despite some statistically significant decreasing trends, an overall increase in BZRA prescriptions was observed throughout the 19-year study period, especially among long-term users of 18-44 years and 65-plus. Zolpidem became the most prescribed BZRA and warrants more attention.
与大多数欧洲指南相反,苯二氮䓬受体激动剂(BZRA)经常以低剂量连续使用,是最常见的长期使用形式。在比利时,BZRA 的使用通过分析过去 24 小时内药物使用的自我报告数据进行监测。这种方法对这些精神活性药物的使用条件提供的了解不足。
描述 2000 年至 2019 年期间在比利时佛兰德地区 BZRA 处方的趋势。
使用一般实践中的发病率登记处的数据进行了基于人群的趋势分析和 2019 年的病例对照研究。
重复的横截面和联合点回归分析揭示了成年患者(18 岁以上)中性别和年龄标准化处方率的趋势。
总体而言,BZRA 处方增加。在 18-44 岁的男性患者中发现总体增幅最大,平均年百分比变化为 2.5(95%CI:0.9,4.3)。在 65 岁以上的女性患者中,自 2006 年以来发现下降,年百分比变化为-0.7(95%CI:-1.3,-0.1)。2019 年,有 12%的登记患者至少接受了一次处方,5%的患者长期使用,腰痛是与 BZRA 处方增加显著相关的最常见疾病,而唑吡坦是最常开的 BZRA(22%)。
尽管存在一些统计学上显著的下降趋势,但在整个 19 年的研究期间,BZRA 处方总体上呈上升趋势,尤其是在 18-44 岁和 65 岁以上的长期使用者中。唑吡坦已成为最常开的 BZRA,值得更多关注。